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Fig. 1: TSAb disturbs hypothalamic-pituitary-thyroid axis
and causes hyperthyroidism
Thyroid hormone (TH) production controlled by positive
and negative regulation. Hypothalamic TRH stimulates
TSH secretion from the anterior pituitary. TSH initiates
thyroid hormone synthesis and release from the thyroid
gland. The synthesis of TRH and TSH subunit genes is
inhibited at the transcriptional level by TH, which also
inhibits posttranslational modification and release of TSH.
The major form of TH in the blood is T4, which is con-
verted to the active T3 within cells by deiodinases. TSAb
continuously stimulates the signaling via TSHR and en-
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Fig. 2 : Preliminary study of in vivo gene introduction by EP
(A) : Histochemical staining for ß-gal activity.
Male ICR mice were injected with 50?g of pBacMam-2-LacZ in saline at the biceps femoris muscle. Cross section of
muscle tissue at a thickness of 10?m after gene introduction by EP. Muscle tissue was excised five days after EP or
vector injection, and stained for ß-gal activity. Magnification: X100.
(B) : Time course of ß-gal activity expressed in muscle tissues.
Male ICR mice were injected with pBacMam-2-LacZ (closed circle) or an empty vector (open circle) as a control, imme-
diately followed by EP. For comparison with a previous DNA transfer procedure, mice were pretreated with (open trian-
gle) or without (open square) cardiotoxin in the muscle. After one week, pBacMam-2-LacZ was injected in the same
cardiotoxin-pretreated sites ß-Gal activities were assayed based on the enzymatic activity in homogenates of the excised
muscle tissues by using ONPG as the substrate. The absorbance of the generated o-nitrophenol was measured at 415
nm. Values are means ? SD for six muscle tissues of three mice.
(C) : Comparison of expression vectors based on ß-gal activity.
Lane-1: control (saline, non-treated), lane-2: pC1-LacZ-IRES-?CD4 (direct DNA injection), lane-3: pBacMam-2-LacZ (di-
rect DNA injection), lane-4: pC1-LacZ-IRES-?CD4 (EP), lane-5: pBacMam-2-LacZ (EP). Values are means ? SD for six
muscle tissues of three mice. Muscles of the mice in the direct DNA injection group were pretreated with cardiotoxin.
(D) : Difference in hTSHR mRNA expression between the EP and direct in vivo injection methods of DNA.
After genetic introduction in ICR mice, mRNA expression of hTSHR was detected by RT-PCR using hTSHR primers,
and that of GAPDH was detected as a control. Numbers within parentheses indicate the number of PCR cycles.
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Fig. 3 : Establishment of the TSHR-expressing cell line,
FMA5 and detection of rhTSHR289His by western
blotting
(A), (B): Detection of hTSHR expression in established cell
line by using flow cytometry.
FMA5 cells were stained with the anti-TSHR monoclonal
Ab, 2C11 (A) or with anti-hCD4 Ab (B). The histogram of
the control CHO-K1 cells that were used for background
staining is shown as an open histogram.
(C): FMA5 (open circle) and control CHO-K1 cells (closed
circle) were incubated with bTSH for 30 min at 37 ?
(0.01-1.0 mI.U./ml). cAMP that was accumulated in the
cells and supernatant was measured by RIA. Values are
the means from three assays in a representative experi-
ment.
(D): Western blotting of rhTSHR289His detected by anti-
His-Ab, digested without/with Endo-F. Antibody binding,
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Fig. 4 : TSHR-stimulating activity in serum of genetically
immunized mice
~ TSAb measurement in FMA5 cells ~
FMA5 cells were incubated for 30 min at 37? with 5?
test serum in Tyrode-HEPES buffer containing 0.5 mM 3-
isobutyl-1-methylxanthine and 0.3? BSA. cAMP accumu-
lation was measured by RIA. BALB/c mice were immu-
nized by in vivo EP with an hTSHR-expressing (shaded
circle), hTSHR289His-expressing (closed circle), or empty
vector (open circle). (A): pC1-IRES-?CD4 vector, (B):
pBacMam-2 vector.
Results are expressed as the percentage of basal cAMP
level released in the presence of control serum from the
mice immunized with the empty vector. TSAb activity was
measured after the second, third, and fourth EP. The
shaded area indicates the mean ? 3 SD of values of 11
or 13 control vector-immunized mice.
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Fig. 5 : Elevation of total serum T4 level in genetically im
munized mice
BALB/c mice were immunized by EP with an hTSHR-
expressing (shaded circle), hTSHR289His-expressing
(closed circle), or empty vector (open circle). (A): pC1-IR
ES-?CD4 vector, (B): pBacMam-2 vector.
Total serum T4 levels in mice were measured one week
after the second, third, and fourth EP. The shaded area








































Fig. 6 : Correlation between TSAb and total T4 value
Correlation between TSAb and the total T4 level after
the fourth EP with the pC1-IRES-?CD4 vector (A, n = 61)
or the pBacMam-2 vector (B, n = 57). The dashed lines
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Fig. 7 : Thyroid gland appearance and its histology in
mice genetically immunized by EP
Appearance of the thyroid gland in mice immunized
with an empty pBacMam-2 (A, control), hTSHR-expressing
(B), and hTSHR289His-expressing vectors (C). Thyroid
glands from hyperthyroidic mice were enlarged unlike the
normal thyroid gland. Frozen sections of the thyroid
glands from normal and hyperthyroidic mice were stained
with hematoxylin and eosin. (D): pBacMam-2 control vec-
tor, (E): pBacMam-2-hTSHR (hyperthyroidic), (F):
pBacMam-2-hTSHR-289His (hyperthyroidic), (G): pC1-hTS
HR289His-IRES-?CD4 (hyperthyroidic), (H): pBacMam-2
control vector, (I): pBacMam-2-hTSHR-289His
(hyperthyroidic). Magnification: (D), (E), (F) and (G) X75,
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Fig. 8 : Detection of antibodies in serum by ELISA using
rhTSHR289His
BALB/c mice were immunized by EP with the hTSHR-
expressing (shaded circle), hTSHR289His-expressing
(closed circle), and empty vectors (open circle). Serum was
collected one week after the second, third, and fourth in
vivo EP. Antibody binding, in 0.25? serum, was measured
by ELISA wells coated with rhTSHR289His protein. (A):
pC1-IRES-?CD4 vector, (B): pBacMam-2 vector. Data
shown are the O.D. values. The shaded area indicates the
mean ? 3SD of values of 11 or 13 control vector-
immunized mice.
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Fig. 9 : Hyperthyroidism caused by long- term immunity to
TSHR
TSAb (A), total T4 (B), and the titer of the anti-hTSHR
antibody (C) in surviving mice were measured eight
months after the last immunization with the pC1-IRES-
?CD4 (A-1, B-1, C-1) and pBacMam-2 (A-2, B-2, C-2) vec-
tors. hTSHR-expressing (shaded circle), hTSHR289His-
expressing (closed circle), and control vectors (open circle).
The shaded area indicates the mean ? 3SD of values of

















Fig. 10 : Pharmacological availability of GD mice verified
by therapeutic effects of PTU
Therapeutic effects of PTU were evaluated by total T4
concentration in serum of GD mice. Hyperthyroidism in
mice was induced by three times genetic immunization of
hTSHR289Fc. GD mice were grouped according to total
T4 value six days before starting PTU administration.
Various dose of PTU was administrated by P.O. for
21days, six days/week. Open circle: control mice; vehicle
control (n=11), closed circle: GD mice; vehicle control (n =
8), open square: GD mice; PTU 10 mg/kg/day (n = 8), open
diamond: GD mice; PTU 20 mg/kg/day (n = 8), open trian-
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Fig. 11 : Trabecular bone loss detected by X-ray
photogram in GD mice
Hyperthyroidism in mice was induced by three times ge-
netic immunization with hTSHR289Fc-expressing vector.
GD mice suffering hyperthyroidism for three months lost
trabecular bone in distal end of the femur (arrowhead).







Fig. 12 : Progressed bone resorption observed by micro-CT
and histological analysis
Hyperthyroidism in mice was induced by three times ge-
netic immunization with hTSHR289His-expression vector.
After six months from GD onset, bone resorption was ob-
served by micro-CT and histological analysis. (A): Micro-
CT analysis of trabecular bone in distal end of the femur
of GD mice. In three-dimensional figures, white parts indi-
cate trabecular bone in distal end of the femur, and green
area indicated bone marrow cavity. GD mice suffering hy-
perthyroidism for six months lost trabecular bone in distal
end of the femur. (B): TRAP-staining of femur specimen in
GD mice. TRAP-positive osteoclasts (arrow) were observed
on inner cortical bone surface.
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Fig. 13 : Elevation of serum phosphate concentration in
GD mice
Hyperthyroidism was induced by three times genetic im-
munization with hTSHR289Fc-expressing vectors (A):
After three times immnization, serum calcium concentra-
tion was measured in GD (n = 3) or control vector-
immunized mice (n = 5 or 6). (B): After three times
immnization, serum phosphate concentration was meas-
ured in GD (n = 3) or control vector-immunized mice (n
=5 or 6). Statistical significance (t-test); ** p < 0.01
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Fig. 14 : Detection of secreted hTSHR mutants proteins by
western blotting
Culture medium was collected four days after
transfection with vectors expressing hTSHR mutants. Se-
creted recombinant proteins in conditioned medium were
analyzed by western blotting after concentration by Ni-
sepharose (A) or protein-A agarose (B). (A): hTSHR-His
mutants, lane 1; control, 2; hTSHR76His, 3; hTSHR98His,
4; hTSHR112His, 5; hTSHR176His, 6; hTSHR197His, 7;
hTSHR210His, 8; hTSHR289His, 9; hTSHR377His. (B)
hTSHR-Fc mutants; lane 1-5; culture medium, lane 6-10;
cell lysate, lane 1, 6; control vector, lane 2, 7;
hTSHR112Fc, lane 3, 8; hTSHR176Fc, lane 4, 9;
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Analysis of pathogenic mechanism in Graves’ disease utilizing model mice
Toshio KANEDA
Department of Phthophysiology, Faculty of Pharmaceutical Sciences, Hoshi University
Graves’ disease (GD) is an organ-specific autoimmune disease caused by stimulatory antibodies of thyrotropin recep-
tors (TSHR) called thyroid-stimulating antibody (TSAb), which result in hyperthyroidism and goitre. Several animal mod-
els of GD have been established for the last decade by immunization with human TSHR (hTSHR)-expressing cells or by
genetic immunization of hTSHR-expressing vector. These progresses have provided us important insights into
pathophysiology of GD. Recently, we also established an improved GD model mice using in vivo electropolation for gene
transferring, which have feature of high incidence rate and of long sustaining hyperthyroidism. In this review, TSAb
epitopes or T cell epitopes in TSHR revealed using model mice are summarized.
